000 03545nam a22004935i 4500
001 978-1-4899-8002-1
003 DE-He213
005 20140220082505.0
007 cr nn 008mamaa
008 131121s2014 xxu| s |||| 0|eng d
020 _a9781489980021
_9978-1-4899-8002-1
024 7 _a10.1007/978-1-4899-8002-1
_2doi
050 4 _aRC261-271
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
082 0 4 _a614.5999
_223
100 1 _aBrown, Kristy A.
_eauthor.
245 1 0 _aObesity and Breast Cancer
_h[electronic resource] :
_bThe Role of Dysregulated Estrogen Metabolism /
_cby Kristy A. Brown, Evan R. Simpson.
264 1 _aNew York, NY :
_bSpringer New York :
_bImprint: Springer,
_c2014.
300 _aIX, 56 p. 9 illus., 7 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aSpringerBriefs in Cancer Research
505 0 _aIntroduction -- Estrogens, adiposity and the menopause -- The link between obesity and breast cancer: Epidemiological evidence -- Adipose-derived and obesity-related factors and breast cancer -- Estrogen biosynthesis -- Therapies aimed at breaking the linkage between obesity and breast cancer -- Conclusions.
520 _aObesity is a risk factor for breast cancer in older women. A number of adipose-derived and obesity-related factors have been shown to affect tumour cell growth. These include adipokines, insulin, IGF-1 and oestrogens. The majority of obesity-related postmenopausal breast cancers are oestrogen-dependent. Since the ovaries no longer produce oestrogens after menopause, and that circulating levels are negligible, it is evident that it is the oestrogens produced locally within the breast adipose that are responsible for the increased growth of breast cancer cells. Aromatase is the enzyme that converts androgens into oestrogens and its regulation is dependent on the activity of a number of tissue-specific promoters. Targeting oestrogen biosynthesis in obesity may be useful for the prevention of breast cancer. Aromatase inhibitors are efficacious at treating postmenopausal breast cancer and recent studies suggest that they may also be useful in the prevention setting. However, these compounds inhibit the catalytic activity of aromatase and as a consequence lead to a number of undesirable side-effects, including arthralgia and possible cognitive defects due to inhibition of aromatase in the bone and brain, respectively. Novel therapies, such as those employed to treat obesity-associated disease, including anti-diabetics, may prove successful at inhibiting aromatase specifically within the breast. This SpringerBrief will explore all of these issues in depth and the authors are in a unique position to write about this topic, having extensive experience in the field of aromatase research.
650 0 _aMedicine.
650 0 _aOncology.
650 0 _aMetabolic diseases.
650 0 _aEnzymes.
650 1 4 _aBiomedicine.
650 2 4 _aCancer Research.
650 2 4 _aMetabolic Diseases.
650 2 4 _aEnzymology.
700 1 _aSimpson, Evan R.
_eauthor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9781489980014
830 0 _aSpringerBriefs in Cancer Research
856 4 0 _uhttp://dx.doi.org/10.1007/978-1-4899-8002-1
912 _aZDB-2-SBL
999 _c92407
_d92407